# MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05903092/  
OnCo record `nct05903092` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of durvalumab, monalizumab and etoposide in lung cancer, run by Hirva Mamdani, now recruiting.

## Summary

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer is a phase 2, interventional study registered as NCT05903092 by Hirva Mamdani, with a registry enrolment figure of 84 participants, started 2023-09-26 and due to reach its primary completion in 2029-10-31. Interventions recorded: Durvalumab; Monalizumab; Carboplatin or Cisplatin; Etoposide. Conditions listed: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer; Limited Stage Small-Cell Lung Cancer. Primary outcome: 1 year Progression Free Survival (PFS); Safety and Tolerability. Lung eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of small cell lung cancer:". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: MOZART
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05903092
- Phase: 2
- Setting: A Phase II Trial of MOnaliZumab in Combination With durvAlumab (MEDI4736) for tReatmenT of Small Cell Lung Cancer (MOZART)
- Sponsor: Hirva Mamdani
- Enrolled: 84

## Sources

- ClinicalTrials.gov NCT05903092: https://clinicaltrials.gov/study/NCT05903092

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Etoposide](https://onco.cc/drugs/etoposide/), [Monalizumab](https://onco.cc/drugs/monalizumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05903092.json